中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
7期
589-591
,共3页
非小细胞肺癌%复方斑蝥胶囊%参一胶囊%紫龙金片%经济学评价
非小細胞肺癌%複方斑蝥膠囊%參一膠囊%紫龍金片%經濟學評價
비소세포폐암%복방반모효낭%삼일효낭%자룡금편%경제학평개
Non-small cell lung cancer%Compound cantharidin capsule%Shenyi capsule%Zilongjin pieces%Economic evalua-tion
目的：对比3种抗癌中成药用于非小细胞肺癌（NSCLC）辅助化疗的临床效果。方法：将2013年1月至2014年1月我院收治的NSCLC患者240例，随机分为4组，每组各60例。对照组采取DP化疗方案；在此化疗方案基础上，A组给予复方斑蝥胶囊、B组给予参一胶囊、C组给予紫龙金片。对4组的疗效、毒副反应、成本-效果比进行比较分析。结果：对照组、A组、B组、C组的总有效率分别为33.3％、56.7％、43.3％、53.3％，4组总有效率组间比较差异有统计学意义（P＜0.05）；A组、C组的有效率均明显高于对照组，差异有统计学意义（P＜0.05）；A组的有效率高于B组、C组，但差异无统计学意义（P＞0.05）。毒副反应主要为骨髓抑制，其次为恶心、呕吐。A组的成本-效果比优于其他3组。结论：复方斑蝥胶囊、参一胶囊、紫龙金片用于NSCLC辅助化疗均具有较好的疗效，且毒副反应少；复方斑蝥胶囊比其他2种中成药的疗效更好、毒副反应更少，且价廉、经济，值得推广应用。
目的：對比3種抗癌中成藥用于非小細胞肺癌（NSCLC）輔助化療的臨床效果。方法：將2013年1月至2014年1月我院收治的NSCLC患者240例，隨機分為4組，每組各60例。對照組採取DP化療方案；在此化療方案基礎上，A組給予複方斑蝥膠囊、B組給予參一膠囊、C組給予紫龍金片。對4組的療效、毒副反應、成本-效果比進行比較分析。結果：對照組、A組、B組、C組的總有效率分彆為33.3％、56.7％、43.3％、53.3％，4組總有效率組間比較差異有統計學意義（P＜0.05）；A組、C組的有效率均明顯高于對照組，差異有統計學意義（P＜0.05）；A組的有效率高于B組、C組，但差異無統計學意義（P＞0.05）。毒副反應主要為骨髓抑製，其次為噁心、嘔吐。A組的成本-效果比優于其他3組。結論：複方斑蝥膠囊、參一膠囊、紫龍金片用于NSCLC輔助化療均具有較好的療效，且毒副反應少；複方斑蝥膠囊比其他2種中成藥的療效更好、毒副反應更少，且價廉、經濟，值得推廣應用。
목적：대비3충항암중성약용우비소세포폐암（NSCLC）보조화료적림상효과。방법：장2013년1월지2014년1월아원수치적NSCLC환자240례，수궤분위4조，매조각60례。대조조채취DP화료방안；재차화료방안기출상，A조급여복방반모효낭、B조급여삼일효낭、C조급여자룡금편。대4조적료효、독부반응、성본-효과비진행비교분석。결과：대조조、A조、B조、C조적총유효솔분별위33.3％、56.7％、43.3％、53.3％，4조총유효솔조간비교차이유통계학의의（P＜0.05）；A조、C조적유효솔균명현고우대조조，차이유통계학의의（P＜0.05）；A조적유효솔고우B조、C조，단차이무통계학의의（P＞0.05）。독부반응주요위골수억제，기차위악심、구토。A조적성본-효과비우우기타3조。결론：복방반모효낭、삼일효낭、자룡금편용우NSCLC보조화료균구유교호적료효，차독부반응소；복방반모효낭비기타2충중성약적료효경호、독부반응경소，차개렴、경제，치득추엄응용。
OBJECTIVE:To evaluate the clinical efficacy of three Chinese patent medicines added to chemotherapy for non-small cell lung cancer(NSCLC). METHODS:240 patients with NSCLC admitted to our hospital from January 2013 to Janu-ary 2014 were randomly divided into four groups,of 60 cases each,with control group given DP chemotherapy alone,group A,B and C given add-on Compound cantharidin capsule,Shenyi capsule,Zilongjin tablets,respectively plus chemotherapy. The effica-cy,toxicity and cost-effectiveness ratio in the four groups were compared. RESULTS:The total effective rates in the control group,group A,B and C were 33.3%,56.7%,43.3% and 53.3%,respectively(P<0.05),with those in group A and C signifi-cantly higher than in the control group (P<0.05). The effective rate in group A was insignificantly higher than in group B or C (P>0.05). Myelosuppression was the major toxicity,followed by nausea and vomiting. The cost-effectiveness ratio in group A was better than in the other three groups. CONCLUSIONS:Compound cantharidin capsule,Shenyi capsule,Zilongjin tablets added to chemotherapy are safe and effective for NSCLC,especially for Compound cantharidin capsule,which is more effective and safer than did Shenyi capsule or Zilongjin tablets,cheap and economical hence is worthy of clinical recommendation.
